




#16/F.D.S.
PTO/SB/08A (10-96
through 10/31/99. OMB 0651-0031
DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid control number. Substitute for form 1449A/PTO		Complete If Known	
 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/031,728 35USC371 of PCT/IL00/00420
		Filing Date	May 1, 2002
		First Named Inventor	Abraham J. Domb
		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	PG 101
Sheet	1	of	3

OIPE JC1172
 SEP 23 2002
 PATENT & TRADEMARK OFFICE

[illegible]

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Office. ³	Number ⁴	Kind Code ⁵ (if known)				
CK		PCT	WO 93/25239 *		Advanced Magnetics Inc.	12-23-1993		
		PCT	WO 95/30020 ~		Immuno-Designed Molecules	12-09-1995		
		PCT	WO 97/46223 *		Genzyme Corporation	12-11-1997		
		PCT	WO 98/01162 ~		Johns Hopkins University	01-15-1998		
		PCT	WO 98/27209 ~		Emory University	06-25-1998		
CK		EP	0 370 810 -		Nippon Oil and Fats Co.	11-23-1989		


Examine Signature	G. K. Bish	Date Considered	4/16/05
----------------------	------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to application.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.**

Please type a plus sign (+) inside this box → ☐



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/031,728 35USC371 of PCT/IL00/00420
		Filing Date	May 1, 2002
		First Named Inventor	Abraham J. Domb
		Group Art Unit	
		Examiner Name	
Sheet 2 of 3	Attorney Docket Number	PG 101	

RECEIVED

SEP 25 2002

TECH CENTER 1600/2900

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
GK		AMSELEM, et al., "Lipospheres for Vaccine Delivery," in <u>Microparticulate Systems for Drug Delivery</u> (Bernstein, et al., eds.), pp. 149-168, 1996.	
		BYK, et al., "Novel cationic lipids for gene delivery and gene therapy," <i>Exp. Opin. Ther. Patents</i> 8(9):1125-1141 (1998).	
		DOMB, et al., "Lipospheres for Controlled Delivery of Substances," in <u>Nanosphere Delivery Systems</u> (Benita, et al., eds.), pp. 377-410, 1996.	
		DOMB, et al., "Polymers in gene therapy," in <u>Frontiers in Biological Polymer Applications</u> (Ottenbrite, ed.) Technomic: Lancaster, Vol. 2, pp. 1-16 (1999).	
		KIELY, et al., "Hydroxylated nylons based on unprotected esterified D-glucaric acid by simple condensation reactions," <i>J. Am. Chem. Soc.</i> 116: 571-578 (1994).	
		LEDLEY, "Nonviral gene therapy: the promise of genes as pharmaceutical products," <i>Hum. Gene Ther.</i> 6(9): 1129-1144 (1995).	
		LIU, et al., "Sugar-containing polyamines prepared using galactose oxidase coupled with chemical reduction," <i>J. Am. Chem. Soc.</i> 121: 466-467 (1999).	
		MAO, et al., "DNA-chitosan nanospheres: derivitization and storage stability," <i>Proc. Intl. Symp. Control Rel. Bioact. Matter</i> 24: 671-672 (1997).	
		PITHA, et al., "Detergents linked to polysaccharides: preparation and effects on membranes and cells," <i>Eur. J. Biochem.</i> 94(1): 11-18 (1979).	
		RICHARDSON, et al., "Evaluation of highly purified chitosan as a potential gene delivery vector," <i>Proceed Intl. Symp. Control Rel. Bioact. Matter</i> 24: 649-650 (1997).	
GK		TAKAKURA, et al., "Control of pharmaceutical properties of soybean tyrosine inhibitor by conjugation with dextran 1: synthesis and characterization," <i>J. Pharm. Sci.</i> 78(2): 117-121 (1999).	


Examiner's Signature	G. Krin	Date Considered	4/16/05
----------------------	---------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number 10/031,728
35USC371 of PCT/IL00/00420

RECEIVED

Filing Date May 1, 2002

First Named Inventor Abraham J. Domb

SEP 25 2002

Group Art Unit

Examiner Name

Attorney Docket Number

PG 101

TECH CENTER 1600/2900

Sheet 3 of 3

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Y ²
GK		TRECO and SELDEN, non viral gene therapy, <i>Molec. Med. Today</i> 1(7):299-348 (1995).	
GK		WALSH, et al., "Combination of drug and gene delivery by gelatin nanospheres for the treatment of cystic fibrosis," <i>Proc. Intl. Sym. Control. Rel. Bioact. Mater.</i> 24: 75-76 (1997).	
GK		YAMAOKA, et al., "Effect of cation content of polycation-type gene carriers on <i>in vitro</i> gene transfer," <i>Chemistry Letters</i> , 1171-1172 (1998).	

Examiner's
Signature

G. Krishnan

Date Considered

4/16/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+